RxDoctor Payments Data

Jonathan Theo, DO

Neurology · Buda, TXNPI 1164919379

Payments from drug & device makers

$16,318in general payments, 2019–2025

Across 121 payments — averaging $134.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Boston Scientific$2K
  • AbbVie$1K
  • Amneal Pharmaceuticals LLC$837
  • Amgen$370
  • Abbott$299
  • plus $847 from 10 others

What the payments were for

  • Consulting fees$1,4139%
  • Grants$10,00061%
  • Travel & lodging$1,5289%
  • Food & beverage$3,10819%
  • Education$2692%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,318 in reported general payments places this provider in the 70th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$189,412
Medicare patients
326
Services billed
14,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine28$271,696
NuplazidPimavanserin Tartrate30$160,283
AustedoDeutetrabenazine13$158,203
RytaryCarbidopa/Levodopa88$106,454
BotoxOnabotulinumtoxina29$38,523
UbrelvyUbrogepant15$20,305
Carbidopa-LevodopaCarbidopa/Levodopa489$11,459
Rasagiline Mesylate32$5,704
Carbidopa20$5,682
Propranolol Hcl ErPropranolol Hcl100$4,715
Primidone90$4,663
AmantadineAmantadine Hcl69$3,938
Carbidopa-Levodopa ErCarbidopa/Levodopa75$2,623
Gabapentin93$1,791
Zonisamide77$1,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$147$429,89941 claims
Acadia Pharmaceuticals IncNuplazid$283$160,28330 claims
Amneal Pharmaceuticals LLCRytary$837$106,45488 claims
AbbVieBotox, Ubrelvy$1,030$58,82844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,246 neurology providers in Texas.

Other neurology in Buda

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →